What is Zacks Research's Forecast for BIO FY2024 Earnings?

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Stock analysts at Zacks Research upped their FY2024 EPS estimates for shares of Bio-Rad Laboratories in a report issued on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $10.18 for the year, up from their prior estimate of $9.46. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2025 earnings at $3.28 EPS, FY2025 earnings at $11.44 EPS, Q1 2026 earnings at $3.15 EPS and Q2 2026 earnings at $3.08 EPS.

BIO has been the topic of a number of other research reports. Citigroup lifted their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Royal Bank of Canada boosted their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $391.80.

Bio-Rad Laboratories Stock Up 1.0 %

Shares of NYSE:BIO traded up $3.18 during midday trading on Monday, hitting $336.09. 330,701 shares of the company's stock were exchanged, compared to its average volume of 246,292. Bio-Rad Laboratories has a 12 month low of $262.12 and a 12 month high of $387.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The stock has a 50 day moving average price of $340.63 and a 200-day moving average price of $316.68. The company has a market cap of $9.41 billion, a PE ratio of -12.30 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. The company had revenue of $649.70 million for the quarter, compared to analysts' expectations of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. Bio-Rad Laboratories's revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.33 earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Teachers Retirement System of The State of Kentucky lifted its stake in Bio-Rad Laboratories by 17.0% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 28,523 shares of the medical research company's stock worth $9,543,000 after purchasing an additional 4,138 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Bio-Rad Laboratories in the third quarter worth $878,000. Y Intercept Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories in the 3rd quarter worth about $2,235,000. MML Investors Services LLC lifted its stake in shares of Bio-Rad Laboratories by 3.1% in the 3rd quarter. MML Investors Services LLC now owns 5,361 shares of the medical research company's stock valued at $1,794,000 after purchasing an additional 159 shares in the last quarter. Finally, Zacks Investment Management acquired a new position in shares of Bio-Rad Laboratories during the third quarter worth about $542,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Insider Activity

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company's stock, valued at approximately $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the business's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This trade represents a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.50% of the company's stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.